File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fphar.2020.00601
- Scopus: eid_2-s2.0-85086521270
- WOS: WOS:000537220600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application
Title | Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application |
---|---|
Authors | |
Keywords | non-alcoholic fatty liver disease herb medicine fatty acids steatosis inflammation |
Issue Date | 2020 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology |
Citation | Frontiers in Pharmacology, 2020, v. 11, p. article no. 601 How to Cite? |
Abstract | Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with high prevalence in the developed countries. NAFLD has been considered as one of the leading causes of cryptogenic cirrhosis and chronic liver disease. The individuals with obesity, insulin resistance and diabetes mellitus, hyperlipidaemia, and hypertension cardiovascular disease have a high risk to develop NAFLD. The related critical pathological events are associated with the development of NAFLD including insulin resistance, lipid metabolism dysfunction, oxidative stress, inflammation, apoptosis, and fibrosis. The development of NAFLD range from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis is characterized by fat accumulation, which represents the early stage of NAFLD. Then, inflammation triggered by steatosis drives early NAFLD progression into NASH. Therefore, the amelioration of steatosis and inflammation is essential for NAFLD therapy. The herbal medicine have taken great effects on the improvement of steatosis and inflammation for treating NAFLD. It has been found out that these effects involved the multiple mechanisms underlying lipid metabolism and inflammation. In this review, we pay particular attention on herbal medicine treatment and make summary about the research of herbal medicine, including herb formula, herb extract and naturals compound on NAFLD. We make details about their protective effects, the mechanism of action involved in the amelioration steatosis and inflammation for NAFLD therapy as well as the clinical application. |
Persistent Identifier | http://hdl.handle.net/10722/284278 |
ISSN | 2023 Impact Factor: 4.4 2023 SCImago Journal Rankings: 1.066 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | XU, Y | - |
dc.contributor.author | GUO, W | - |
dc.contributor.author | ZHANG, C | - |
dc.contributor.author | CHEN, F | - |
dc.contributor.author | Tan, HY | - |
dc.contributor.author | Li, S | - |
dc.contributor.author | Wang, N | - |
dc.contributor.author | Feng, Y | - |
dc.date.accessioned | 2020-07-20T05:57:27Z | - |
dc.date.available | 2020-07-20T05:57:27Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Frontiers in Pharmacology, 2020, v. 11, p. article no. 601 | - |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | http://hdl.handle.net/10722/284278 | - |
dc.description.abstract | Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with high prevalence in the developed countries. NAFLD has been considered as one of the leading causes of cryptogenic cirrhosis and chronic liver disease. The individuals with obesity, insulin resistance and diabetes mellitus, hyperlipidaemia, and hypertension cardiovascular disease have a high risk to develop NAFLD. The related critical pathological events are associated with the development of NAFLD including insulin resistance, lipid metabolism dysfunction, oxidative stress, inflammation, apoptosis, and fibrosis. The development of NAFLD range from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis is characterized by fat accumulation, which represents the early stage of NAFLD. Then, inflammation triggered by steatosis drives early NAFLD progression into NASH. Therefore, the amelioration of steatosis and inflammation is essential for NAFLD therapy. The herbal medicine have taken great effects on the improvement of steatosis and inflammation for treating NAFLD. It has been found out that these effects involved the multiple mechanisms underlying lipid metabolism and inflammation. In this review, we pay particular attention on herbal medicine treatment and make summary about the research of herbal medicine, including herb formula, herb extract and naturals compound on NAFLD. We make details about their protective effects, the mechanism of action involved in the amelioration steatosis and inflammation for NAFLD therapy as well as the clinical application. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology | - |
dc.relation.ispartof | Frontiers in Pharmacology | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | non-alcoholic fatty liver disease | - |
dc.subject | herb medicine | - |
dc.subject | fatty acids | - |
dc.subject | steatosis | - |
dc.subject | inflammation | - |
dc.title | Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application | - |
dc.type | Article | - |
dc.identifier.email | Tan, HY: hyhtan@hku.hk | - |
dc.identifier.email | Li, S: lishaha@hku.hk | - |
dc.identifier.email | Wang, N: ckwang@hku.hk | - |
dc.identifier.email | Feng, Y: yfeng@hku.hk | - |
dc.identifier.authority | Wang, N=rp02075 | - |
dc.identifier.authority | Feng, Y=rp00466 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fphar.2020.00601 | - |
dc.identifier.scopus | eid_2-s2.0-85086521270 | - |
dc.identifier.hkuros | 311481 | - |
dc.identifier.volume | 11 | - |
dc.identifier.spage | article no. 601 | - |
dc.identifier.epage | article no. 601 | - |
dc.identifier.isi | WOS:000537220600001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 1663-9812 | - |